Challenges in talking to stock analysts
© iStockphoto.com/Andrea Zanchi
Kathleen Raven was writing about an Alzheimer's drug when she asked for comment from an analyst who foresaw its failure in late-stage trials. His response: "I’m sorry, I don’t talk to the media." He wasn't the only source who clammed up, Raven writes on Embargo Watch. Their excuses: "Some said they consulted for the drug company ... Another explained he simply didn't have time to give an interview. Yet another potential source gave no explanation and simply hung up."